Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled Phase 3 Trial of Azathioprine for the Prevention of Relapse in Myelin-oligodendrocyte-glycoprotein (MOG)-Antibody Associated Disease

NCT05349006 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT05349006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05349006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled Phase 3 Trial of Azathioprine for the Prevention of Relapse in Myelin-oligodendrocyte-glycoprotein (MOG)-Antibody Associated Disease
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 3
Overall status
Recruiting
Start date
December 12, 2023
Completion date
December 12, 2029
Enrollment
126 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system inflammation, mog-igg associated disease